[1]吴亚男,李红霞*,孟宪宁,等.子宫内膜异位症及卵巢癌患者血清脑源性神经营养因子水平的表达及意义[J].中国计划生育和妇产科,2018,(9):32-34,38.
　WU Ya-nan,LI Hong-xia*,MENG Xian-ning,et al.Expression and significance of serum BDNF in patients with endometriosis and ovarian cancer[J].Chinese Journal of Family Planning & Gynecotokology,2018,(9):32-34,38.
点击复制

子宫内膜异位症及卵巢癌患者血清脑源性神经营养因子水平的表达及意义
分享到：

《中国计划生育和妇产科》[ISSN:1674-4020/CN:51-1708/R]

卷:
期数:
2018年9期
页码:
32-34,38
栏目:
论著与临床
出版日期:
2018-09-25

文章信息/Info

Title:
Expression and significance of serum BDNF in patients with endometriosis and ovarian cancer
作者:
吴亚男; 李红霞*; 孟宪宁; 王宏利; 魏玲; 霍志平
中国石油天然气集团公司中心医院妇产科
Author(s):
WU Ya-nan; LI Hong-xia*;  MENG Xian-ning;  WANG Hong-li;  WEI Ling;  HUO Zhi-ping
Department of Obstetrics and Gynecology，China National Petroleum Corporation Central Hospital，Langfang Heibei 065000，P.R.China
关键词:
子宫内膜异位症; 卵巢癌; 脑源性神经营养因子
Keywords:
endometriosis;  ovarian cancer;  brain-derived neurotrophic factor
分类号:
R 711.71,R 737.31
摘要:
目的本研究旨在探讨子宫内膜异位症（endometriosis，EMs）及卵巢癌患者血清中脑源性神经营养因子（brain-derived neurotrophic factor，BDNF）水平的表达及意义。方法收集2014年5月至2017年8月中国石油天然气集团公司中心医院收治的EMs患者82例（内异症组）和卵巢癌患者96例（卵巢癌组），以及同期来院体检的健康女性50例（对照组）。应用酶联免疫吸附测定（enzyme-linked immunosorbent assay，ELISA）方法检测患者血清中BDNF的表达水平，比较3组间的差异。比较按照美国生育学会（American Fertility Society，AFS）不同分期的EMs患者血清BDNF水平的表达差异，并分析卵巢癌患者血清BDNF水平与临床病理特征之间的关系。结果术前内异症组与卵巢癌组的血清BDNF水平均明显高于对照组，而卵巢癌患者的血清BDNF水平又明显高于内异症组；术后内异症组与卵巢癌组的血清BDNF水平均较术前明显降低，但仍高于对照组，差异均有统计学意义（P＜005）；术后卵巢癌患者的血清BDNF水平与内异症组患者比较差异无统计学意义（P＞005）。不同AFS分期的内异症患者的血清BDNF水平比较，Ⅰ~Ⅱ期患者明显低于Ⅲ~Ⅳ期（P＜005）；出现淋巴结转移的卵巢癌患者血清BDNF水平与无转移患者间比较，差异无统计学意义（P＞005）；浆液型肿瘤患者血清BDNF水平明显高于黏液型肿瘤、透明细胞癌和子宫内膜样腺癌（P＜005），但黏液型肿瘤、透明细胞癌和子宫内膜样腺癌的血清BDNF水平比较差异无统计学意义（P＞005）；临床分期Ⅰ~Ⅱ期患者的血清BDNF水平明显低于Ⅲ~Ⅳ期，差异有统计学意义（P＜005）。结论BDNF在卵巢癌与EMs患者的血清中均呈高表达，但卵巢癌患者的表达更高。血清BDNF水平在不同AFS分期的EMs患者间存在差异，也与卵巢癌患者的组织学类型和临床分期有关。血清BNDF蛋白在卵巢癌与EMs的鉴别方面具有一定意义。
Abstract:
ObjectiveThis study aimed to investigate the expression and significance of serum brain-derived neurotrophic factor（BDNF） levels in patients with endometriosis(EMs) and ovarian cancer. Methods82 patients with EMs collected in China National Petroleum Corporation Central Hospital from May 2014 to August 2017 were set up as EMs group and 96 cases of ovarian cancer as ovarian cancer group.50 healthy women(normal endomtrium) were collected as control group at the same time. Enzyme-linked immunosorbent assay(ELISA) was used to detect the expression level of BDNF in the serum of patients and the differences of the three groups were compared. To compare the differences of serum BDNF levels in EMs patients with different AFS stages and analyze the relationship between the serum level of BDNF and clinicopathological features in patients with ovarian cancer. ResultsThe levels of serum BDNF in preoperative EMs group and ovarian cancer group were significantly higher than those in control group, while the levels of serum BDNF in ovarian cancer patients were significantly higher than those in EMs group. The serum levels of BDNF in patients with EMs and ovarian cancer were significantly improved compared with those before operation, but still higher than those in control group, the differences were statistically significant(P<005).However, the serum BDNF level in patients with ovarian cancer was not significantly different from that in patients with EMs group(P>005).The difference of serum BDNF levels in patients with EMs with different stages of AFS was compared,the patients in stage I to II were significantly lower than stage III to IV(P＜005).There was no significant difference in serum BDNF between patients with lymph node metastasis and those without metastasis(P>005).Serum BDNF levels in serous type patients were significantly higher than those in mucinous type of tumors, clear cell carcinoma and endometrial adenocarcinoma(P<005).However, there was no significant difference in serum BDNF levels between mucinous tumor, clear cell carcinoma and endometrioid adenocarcinoma(P>005).Serum BDNF levels in patients with clinical stages Ⅰ~Ⅱ were significantly lower than those in patients with stage Ⅲ~Ⅳ. The differences were statistically significant(P<005). Conclusion BDNF is highly expressed in the serum of patients with ovarian cancer and EMs, but the expression of BDNF is higher in ovarian cancer patients. Serum BDNF levels differed between patients with EMs at different AFS stages and also with histological type and clinical stage in patients with ovarian cancer. Serum BNDF protein has certain significance in ovarian cancer and EMs identification.

参考文献/References:

［1］HAN S-j, JUNG S Y, WU S-p, et al. Estrogen receptor β modulates apoptosis complexes and the inflammasome to drive the pathogenesis of endometriosis ［J］. Cell, 2015, 163 (4): 960-974. ［2］WANG Shu, QIU Lin, LANG Jing-he, et al. Clinical analysis of ovarian epithelial carcinoma with coexisting pelvic endometriosis ［J］. American Journal of Obstetrics and Gynecology, 2013, 208 (5): 411-413. ［3］WANG Yi-ying, MANG M, WANG Yu-e, et al. Tubal origin of ovarian endometriosis and clear cell and endometrioid carcinoma ［J］. American Journal of Cancer Research, 2015, 5 (3): 869-879. ［4］MASOUMI-MOGHADDAM S, AMINI A, WEI A-q, et al. Sprouty 2 protein in prediction of post-treatment ascites in epithelial ovariancancer treated with adjuvant carbotaxol chemotherapy ［J］. American Journal of Cancer Research, 2015, 5 (8): 2498-2507. ［5］ELGAAEN B V, OLSTAD O K, SANDVIK L, et al. ZNF385B and VEGFA are strongly differentially expressed in serous ovarian carcinomas and correlate with survival ［J］. PLOS One, 2012, 7 (9): e46317. ［6］SIAMAKPOUR-REIHANI S, OWZAR K, JIANG C, et al. Prognostic significance of differential expression of angiogenic genes in women with high-grade serous ovarian carcinoma ［J］. Gynecologic Oncology, 2015, 139 (1): 23-29. ［7］WESSELS J M, LEYLAND N, AGARWAL S K, et al. Estrogen induced changes inuterine brain-derived neurotrophie factor and its receptors ［J］. Hum Reprod,20l5, 30 (4): 925-936. ［8］ZHANG Q-y, GUAN Q, WANG Y, et al. BDNF Val66Met polymorphism is associated with Stage III-IV endometriosis and poor in vitro fertilization outcome ［J］. Human Reproduction (Oxford, England), 2012, 27(6): 1668-1675. ［9］CHATTERJEE S, DEY S, CHOWDHURY R G, et al. Pregnancy outcome in preoperative danazol treatment followed by laparoscopic correction in infertility associated with endometriosis ［J］. Indian Med Assoc, 2012, 110 (10): 694-699. ［10］林仲秋，谢玲玲，李晶FIGO 2013卵巢癌、输卵管癌、腹膜癌新分期解读 ［J］中国实用妇科与产杂志，2013，29（12）：921-923 ［11］马亚琪，王昀，刘爱军，等WHO (2014)卵巢肿瘤组织学分类 ［J］诊断病理学杂志，2014，21（8）：530-531 ［12］Pavone ME, Lyttle BM. Endometriosis and ovarian cancer: links,risks, and challenges faced ［J］. Int J Womens Health, 2015, 7（7）: 663-672. ［13］WOO M G, XUE K, LIU J, et al. Calpain-mediated processing of p53-associated parkin-like cytoplasmic protein(PARC) affects chemosensitivity of human ovarian cancer cells by promoting p53 subcellular trafficking ［J］. Journal of Biological Chemistry, 2012, 287 (6): 3963-3975. ［14］李明伟，刘继红TrkB 及其配体BDNF 在卵巢上皮癌中的表达及其临床意义 ［J］中国妇产科临床杂志，2012，13（2）：122-125 ［15］WESSELS J M, KAY V R, LEYLAND N A, et al. Assessing brain-derived neurotrophic factor as a novel clinical marker of endometriosis ［J］. Fertility and Sterility, 2016, 105 (1): 119-128.e5.

相似文献/References:

[1]苏慧明,徐燕,李晶,等.E-钙粘附素在子宫内膜异位症盆腔腹膜病灶的表达[J].中国计划生育和妇产科,2010,(01):0.
　SU Hui-ming,XU Yan,LI Jing,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2010,(9):0.
[2]李桂兰.青春期子宫内膜异位症的诊治进展[J].中国计划生育和妇产科,2010,(03):0.
[3]韦晓娜,覃红萍.孕三烯酮配伍小剂量米非司酮治疗子宫内膜异位症64例效果观察[J].中国计划生育和妇产科,2010,(04):0.
[4]李成龙,冷金花.子宫内膜异位症与雌、孕激素受体关系的研究进展[J].中国计划生育和妇产科,2010,(04):0.
[5]伍军平,陈宝霞,罗新,等.妊娠晚期胎死宫内合并卵巢癌破裂1例[J].中国计划生育和妇产科,2011,(03):0.
[6]关铮.深部浸润型子宫内膜异位症相关问题探讨[J].中国计划生育和妇产科,2011,(04):0.
[7]张瑞霞,刘增娟,谢伟,等.腹腔镜诊断盆腔子宫内膜异位症及对不孕症患者的疗效观察[J].中国计划生育和妇产科,2012,(02):0.
　ZHANG Rui-xia,LIU Zeng-juan,XIE Wei,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2012,(9):0.
[8]梁寿珺,范余娟,黄尹,等.血管内皮生长因子+936TC基因多态性同子宫内膜异位症遗传易感性的Meta分析[J].中国计划生育和妇产科,2012,(04):0.
　LIANG Shou-jun,FAN Yu-juan*,HUANG Yin,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2012,(9):0.
[9]张爱臣,佟玲玲.卵巢癌的诊治进展[J].中国计划生育和妇产科,2013,(01):0.
　ZHANG Ai-chen,TONG Ling-ling.[J].Chinese Journal of Family Planning & Gynecotokology,2013,(9):0.
[10]范俊,栾少红,李晓林,等.口服避孕药在子宫内膜异位症治疗中的作用[J].中国计划生育和妇产科,2013,(02):0.
　FAN Jun,LUAN Shao-hong,LI Xiao-lin,et al.[J].Chinese Journal of Family Planning & Gynecotokology,2013,(9):0.
[11]陈彩香*,文锦娣,杨海珍.子宫内膜异位症相关卵巢癌患者临床特点分析[J].中国计划生育和妇产科,2018,(4):62.
　CHEN Cai-xiang*,WEN Jin-di,YANG Hai-zhen.Clinical characteristics of patients with endometriosis associated ovarian cancer[J].Chinese Journal of Family Planning & Gynecotokology,2018,(9):62.

备注/Memo

备注/Memo:
河北省廊坊市科学技术局科研课题(项目编号：2017013145)
更新日期/Last Update: 2018-09-25